This article first appeared on GuruFocus .
-
Revenue:INR8,042 million, up 17.1% year-on-year and 5.7% quarter-on-quarter.
-
EBITDA Margin:Adjusted for one-time nonrecurring M&A costs at 18.2%, down by 2% sequentially.
-
Net Income (PAT):INR1,021 million, a growth of 11.4% year-on-year.
-
PAT Margin:12.7%, a reduction of 2.6% sequentially.
-
Effective Tax Rate (ETR):23.3% for Q2.
-
Enterprise Segment Growth:8.1% quarter-on-quarter.
-
Brand Activation Segment:Decreased by 15.8%.
-
Top 5 Customers Growth:4.5% quarter-on-quarter.
-
Active Customer Base:Increased to 76 from 70 in the last quarter.
-
Cash Balances:USD210 million as of September 30, 2025.
-
DSOs:71 days, net of unearned and unbilled revenue.
-
BioPharm Acquisition:Completed for approximately USD65 million.
-
WARN & CO Acquisition:Completed for GBP2 million plus future performance-linked payout.
-
Warning! GuruFocus has detected 2 Warning Signs with BOM:538666.
-
Is NSE:INDGN fairly valued? Test your thesis with our free DCF calculator.
Release Date: October 31, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Indegene Ltd ( NSE:INDGN ) reported a 17.1% year-on-year revenue growth in Q2 FY26, reaching INR8,042 million.
-
The company successfully converted two more customers into paying clients for its Tectonic platform, increasing its customer base.
-
Indegene Ltd ( NSE:INDGN ) has made strategic acquisitions, including BioPharm and WARN & CO, to enhance its capabilities and market reach.
-
The company is seeing increased interest in its GenAI-based capabilities, particularly in digital content and medical writing applications.
-
Indegene Ltd ( NSE:INDGN ) hosted a successful in-person Indegene Digital Summit, gaining valuable insights and reinforcing its AI-focused strategy.
Negative Points
-
The EBITDA margin for Q2 FY26 decreased by 2% sequentially, primarily due to annual wage hikes and increased marketing expenses.
-
The company anticipates a 1.5% margin compression in the near term due to investments in growth initiatives.
-
Indegene Ltd ( NSE:INDGN ) experienced a degrowth in its Brand Activation segment by 15.8% in Q2 FY26.
-
The largest customer of Indegene Ltd ( NSE:INDGN ) showed a revenue decline due to a change in the onsite-offshore mix.
-
The company faces challenges in closing deals in its Brand Activation segment, impacting its growth trajectory.
Q & A Highlights
Q: Can you explain the increase in operating expenses and the impact of employee cost hikes on margins? Also, what is the outlook for margins over the next few years? A: The increase in operating expenses is due to M&A costs, the IDS 2025 event, and higher technology costs related to GenAI. Employee cost hikes, effective from July 2025, resulted in a 2.1% margin dilution. We expect margins to recover to previous levels over the next 6 to 8 quarters as investments start yielding returns. (Suhas Prabhu, CFO)
Q: How is the business mix evolving with your top clients, and what is the outlook for growth with them? A: Our top 5 customers have shown growth, with a 4.5% increase quarter-on-quarter. The largest customer experienced a revenue mix change from onsite to offshore, which impacted revenue but is positive for margins. We have a strong pipeline and are optimistic about growth with our largest customer in the near to mid-term. (Manish Gupta, CEO)
Q: What is the expected headcount trend considering investments in AI and productivity? A: We anticipate headcount growth, but at a slower rate than revenue growth, due to increased productivity and efficiency from AI investments. We are also hiring ahead of demand to prepare for future growth. (Suhas Prabhu, CFO)
Q: What growth do you anticipate from recent acquisitions, and how will they impact margins? A: The acquisitions are expected to contribute to growth, but we anticipate a 1% to 1.5% margin compression in the near term due to upfront investments. We expect margins to recover as growth accelerates over the next 6 to 8 quarters. (Manish Gupta, CEO)
Q: How does the current environment compare to past disruptions, and what opportunities do you see? A: The current disruptions are less severe than past ones, and the industry is stabilizing. We see opportunities in digital transformation and AI, as companies seek efficiency amid ongoing drug pricing pressures. This aligns with our offerings and positions us well for growth. (Manish Gupta, CEO)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
